Volume 30, Number 1—January 2024
CME ACTIVITY - Synopsis
Auritidibacter ignavus, an Emerging Pathogen Associated with Chronic Ear Infections
Sophie Roth
, Maximilian Linxweiler, Jacqueline Rehner, Georges-Pierre Schmartz, Sören L. Becker, and Jan Philipp Kühn
, Maximilian Linxweiler, Jacqueline Rehner, Georges-Pierre Schmartz, Sören L. Becker, and Jan Philipp Kühn
Table
Antimicrobial drug susceptibility patterns for 10 drugs of 3 Auriditibacter ignavus isolates from patients with chronic ear infections, Germany*
| Isolate | MIC, mg/L |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| PEN | CRX | AMS | MEM | VAN | LIN | CLI | DOX | SXT | CIP | |
| 1 | 0.38 | 0.5 | 0.25 | 1.5 | 0.064 | 0.5 | 32 | 0.5 | 0.094 | 32 |
| 2 | 0.19 | 0.094 | 0.125 | 0.38 | 0.125 | 0.75 | 2 | 0.064 | 0.008 | 16 |
| 3 |
0.125 |
0.125 |
0.25 |
0.5 |
0.064 |
0.38 |
1.5 |
0.125 |
0.19 |
12 |
| *Testing was performed by using epsilometry on Mueller-Hinton-Agar with 5% sheep blood. AMS, ampicillin/sulbactam; CRX, cefuroxime; CIP, ciprofloxacin; CLI, clindamycin; DOX, doxycycline; LIN, linezolid; MEM, meropenem; PEN, penicillin, SXT, trimethoprim/sulfamethoxazole; VAN, vancomycin. |
||||||||||
Page created: November 01, 2023
Page updated: December 20, 2023
Page reviewed: December 20, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.